Tango also retains the rights to identify targets outside the immune evasion space as it continues to build its wholly owned pipeline.
February 19, 2020
The company strives to transform and simplify care for people with life-threatening illnesses around the world.
For more information on Gilead Sciences, please visit the company’s website at “We are disappointed in this outcome and will evaluate the points raised in the CRL for discussion with the FDA.
September 01, 2020
BACK TO MAIN MENU June 01, 2020
August 11, 2020
For the latest updates on our ongoing response to COVID-19, please
In addition, Tango has signed two strategic collaborations with Gilead Sciences and has received a total of $175 million in upfront payments.
Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network Gilead Sciences Statement on State Attorneys General Letter on Remdesivir Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19 Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in …
July 13, 2020
Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
July 24, 2020
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that FDA and other regulatory agencies may not approve magrolimab for the treatment of MDS and other indications, and any marketing approvals, if granted, may have significant limitations on its use.
Magrolimab is being developed in several hematologic and solid tumor malignancies, including MDS.
March 10, 2020
In addition, Gilead will have the right to option up to 15 programs over the seven-year collaboration for up to $410 million per program in opt-in, extension and milestone payments.
July 16, 2020
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical studies involving filgotinib, including the MANTA and MANTA-RAy studies, and the possibility that the parties may be unable to complete one or more of such studies in the currently anticipated timelines or at all.
February 10, 2020